In this project, the overall goal is to design novel molecular MRI methods that are minimally invasive or totally noninvasive and, as such, have a high potential of being translated rapidly into the clinic to be used for tumor assessment and monitoring of treatment. Towards this goal, we exploit so-called chemical exchange saturation transfer (CEST) contrast, which is generated through magnetic labeling of exchangeable protons (such as NH and OH) on either exogenous or endogenous agents, followed by a physical transfer (chemical exchange) of this label to water protons, which allows detection using MRI. To reach our ultimate goal of fast human translation, we will focus our efforts on diamagnetic, biodegradable, non-metallic compounds. Specifically, we will exploit the body's own building blocks, proteins and carbohydrates as CEST biomarkers and develop MRI technology to detect these markers. Tumors are generally characterized by an increased content of small mobile proteins and peptides, rapid glucose metabolism, and increased permeability between blood vessels and extravascular extracellular space. The overall goal therefore is to develop MRI pulse sequence technology and theory for detecting mobile protein content, glucose delivery and metabolism, and tumor perfusion.
Our first aim i s to assess protein content by employing nuclear interactions within these macromolecules (cross-relaxation) combined with the exchange ofthe protein's amide protons to water protons. In the second aim, glucose metabolism and tumor perfusion will be assessed by monitoring the uptake of non-labeled D-glucose using CEST. These technologies are expected to be applicable for most tumor types, but to demonstrate their applicability, we will apply them first to two human breast cancer lines: less aggressive (MCF-7) and highly aggressive and metastatic (MDA-MB-231). This will be done both ex vivo, in perfused cells and, in vivo, on xenografts in mice. As a third aim, we will perform pilot studies in patients to show feasibility of rapid translation.
These aims are expected to result in the availability of molecular MRI technologies in vivo that are suitable for immediate application in humans. Once established, we expect that these methods can be used for tumor detection, imaging tumor perfusion and metabolism, assessing tumor malignancy, and monitoring tumor treatment. This is expected to reduce false-positive detection rates by functioning as an add-on for current high-volume screening approaches and to improve treatment monitoring by MRI.
Breast cancer is the most frequently diagnosed type of cancer in women and the second leading cause of death. Prevention, early diagnosis, and treatment are the three broad challenges for reducing mortality from breast cancer. In this project biocompatible MR technologies will be developed that can help to address the latter two clinical challenges using safe and practically noninvasive approaches.
|Winnard Jr, Paul T; Bharti, Santosh K; Penet, Marie-France et al. (2016) Detection of Pancreatic Cancer-Induced Cachexia Using a Fluorescent Myoblast Reporter System and Analysis of Metabolite Abundance. Cancer Res 76:1441-50|
|Chan, Kannie W Y; Jiang, Lu; Cheng, Menglin et al. (2016) CEST-MRI detects metabolite levels altered by breast cancer cell aggressiveness and chemotherapy response. NMR Biomed 29:806-16|
|Azad, Babak Behnam; Chatterjee, Samit; Lesniak, Wojciech G et al. (2016) A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts. Oncotarget 7:12344-58|
|Penet, Marie-France; Chen, Zhihang; Mori, Noriko et al. (2016) Magnetic Resonance Spectroscopy of siRNA-Based Cancer Therapy. Methods Mol Biol 1372:37-47|
|Xu, Xiang; Yadav, Nirbhay N; Zeng, Haifeng et al. (2016) Magnetization transfer contrast-suppressed imaging of amide proton transfer and relayed nuclear overhauser enhancement chemical exchange saturation transfer effects in the human brain at 7T. Magn Reson Med 75:88-96|
|Mascini, Nadine E; Cheng, Menglin; Jiang, Lu et al. (2016) Mass Spectrometry Imaging of the Hypoxia Marker Pimonidazole in a Breast Tumor Model. Anal Chem 88:3107-14|
|Chatterjee, Samit; Lesniak, Wojciech G; Gabrielson, Matthew et al. (2016) A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. Oncotarget 7:10215-27|
|Penet, Marie-France; Kakkad, Samata; Pathak, Arvind P et al. (2016) Structure and Function of a Prostate Cancer Dissemination Permissive Extracellular Matrix. Clin Cancer Res :|
|Lesniak, Wojciech G; Oskolkov, Nikita; Song, Xiaolei et al. (2016) Salicylic Acid Conjugated Dendrimers Are a Tunable, High Performance CEST MRI NanoPlatform. Nano Lett 16:2248-53|
|Behnam Azad, Babak; Lisok, Ala; Chatterjee, Samit et al. (2016) Targeted Imaging of the Atypical Chemokine Receptor 3 (ACKR3/CXCR7) in Human Cancer Xenografts. J Nucl Med 57:981-8|
Showing the most recent 10 out of 198 publications